BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 4, 2017
View Archived Issues
Medsenic's arsenic trioxide awarded E.U. orphan drug designation for GvHD, begins phase II trial
Read More
Novel prototypical peptidomimetic inhibitor demonstrates efficacy in models of AML
Read More
IMPDH inhibition as a promising new therapeutic strategy against MLL-fusion leukemia
Read More
AMPK identified as a novel therapeutic target in acute lymphoblastic leukemia
Read More
Researchers identify a novel target for AML and MDS
Read More
Xenikos obtains funding to support T-Guard development
Read More
Flamel Technologies now Avadel Pharmaceuticals
Read More
Axsome Therapeutics cleared to begin phase II/III study of AXS-05 in Alzheimer's
Read More
Bayer Pharma patents muscarinic acetylcholine M2 receptor PAMs
Read More
University of Florida discloses aminoacyl-tRNA synthetase inhibitors
Read More
Zynerba Pharmaceuticals commences FAB-C study of ZYN-002 gel
Read More
Abeona Therapeutics' ABO-201 granted orphan drug designation in Europe
Read More
Inventiva initiates patient enrollment in phase IIb study of IVA-337
Read More
Almirall describes JAK inhibitors
Read More
Soliqua available in U.S.
Read More
Adhaere Pharmaceuticals presents anticancer agents
Read More
Kite Pharma submits IND for phase I study of KITE-718
Read More
GSK closes agreement to divest non-core assets to Aspen
Read More
FDA grants priority review to Stivarga sNDA for hepatocellular carcinoma
Read More
Astellas Pharma discloses dopamine D1 receptor PAMs
Read More
Seattle Genetics presents new clinical data for vadastuximab talirine
Read More
Agile reports phase III topline results for Twirla hormonal contraceptive patch
Read More
Newron Pharmaceuticals reports promising results for evenamide in schizophrenia
Read More
Inspyr Therapeutics to study mipsagargin combination therapies
Read More
NewVac's phase II study of quisinostat meets primary endpoints
Read More
Inotek reports topline results from pivotal trial of trabodenoson for glaucoma
Read More
Acura explores financing and strategic alternatives
Read More
CymaBay Therapeutics signs license agreement with Kowa for arhalofenate in U.S.
Read More
Cellectis submits IND to begin phase I trials of UCART-123
Read More